Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues increased the risk of confounding study results and the likelihood of disruptive cost-reduction measures, leading to an overstatement of Jasper's business and financial prospects [5].

Core Viewpoint - Jasper Therapeutics, Inc. is facing a class action lawsuit for investors who purchased securities during the specified class period, following a significant drop in stock price due to issues in a clinical trial [1][3]. Group 1: Class Action Details - The Portnoy Law Firm is advising Jasper investors of a class action on behalf of those who bought securities between November 30, 2023, and July 3, 2025 [1]. - Investors have until November 18, 2025, to file a lead plaintiff motion [1]. Group 2: Stock Price Impact - Following the announcement of issues related to a drug product lot in a clinical trial, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share on July 7, 2025 [3]. Group 3: Clinical Trial Update - On July 7, 2025, Jasper released updated data from its BEACON Phase 1b/2a study, indicating that results from certain dose cohorts were confounded by issues with one drug product lot [3]. - The company is currently investigating the drug product lot and expects to have results in the coming weeks [3]. Group 4: Legal Representation - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific allegations of misleading statements and undisclosed issues affecting their business operations and financial prospects [1]. Quanex Building Products Corporation (NYSE: NX) - Class Period: December 12, 2024 – September 5, 2025 - Allegations include significant underinvestment in tooling and equipment maintenance, leading to degraded conditions and potential significant costs that could delay expected benefits from integration efforts [2]. Jasper Therapeutics, Inc. (NASDAQ: JSPR) - Class Period: November 30, 2023 – July 3, 2025 - Allegations focus on the lack of necessary controls for third-party manufacturers, increasing risks to clinical trial results and overstating the company's financial and product prospects [3]. KBR, Inc. (NYSE: KBR) - Class Period: May 6, 2025 – June 19, 2025 - Allegations state that the company misrepresented the status of its partnership with TRANSCOM, despite known concerns regarding contract fulfillment, leading to misleading statements about business operations [4]. RCI Hospitality Holdings, Inc. (NASDAQ: RICK) - Class Period: December 15, 2021 – September 16, 2025 - Allegations include engagement in tax fraud and bribery to cover up these actions, resulting in understated legal risks and misleading statements about the company's business and operations [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading nat ...

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Accessibility StatementSkip Navigation BENSALEM, Pa., Oct. 1, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ:Â JSPR). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JS ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a le ...

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 30, 2023, to July 3, 2025, seeking damages for affected investors [1][2]. Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for mast cell-driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and Asthma [3]. - The lead product candidate, briquilimab, is a monoclonal antibody aimed at blocking the stem cell factor (SCF) from signaling through the CD117 (c-Kit) receptor, which is believed to be crucial for mast cell survival [3]. Financial Developments - In 2024, Jasper completed an oversubscribed financing round of $50 million to strengthen its balance sheet and support briquilimab's development, extending its cash runway through the third quarter of 2025 [3]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to concerns over drug lot issues and halted studies [7]. Clinical Trials and Issues - Jasper commenced a Phase 1b/2a clinical study for CSU (BEACON Study) in November 2023 and another for allergic asthma (ETESIAN Study) in December 2024 [3]. - On July 7, 2025, Jasper reported confounding results in the BEACON Study due to issues with a specific drug product lot, leading to the halting of the ETESIAN Study and a pause in SCID development [7][9]. Management and Operational Changes - Following the announcement of the drug lot issues, Jasper revealed a corporate reorganization, including a workforce reduction of approximately 50% and a focus on developing briquilimab for chronic urticaria [9]. - The Chief Medical Officer, Edwin Tucker, is set to depart from his role effective August 1, 2025 [9]. Market Reactions - Analysts reacted to the developments, with BMO Capital Markets downgrading Jasper to market perform and lowering its price target from $6.77 to $4.00, citing potential drug lot issues and uncertainties around dose-response [8].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Jasper Therapeutics, Inc. during the specified Class Period, alleging misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Jasper Therapeutics securities between November 30, 2023, and July 3, 2025 [1]. - The lawsuit claims that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by November 18, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTIC. ...